JP2003508453A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003508453A5 JP2003508453A5 JP2001520155A JP2001520155A JP2003508453A5 JP 2003508453 A5 JP2003508453 A5 JP 2003508453A5 JP 2001520155 A JP2001520155 A JP 2001520155A JP 2001520155 A JP2001520155 A JP 2001520155A JP 2003508453 A5 JP2003508453 A5 JP 2003508453A5
- Authority
- JP
- Japan
- Prior art keywords
- risk
- inhibitor
- cyclooxygenase
- angiotensin
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003087 receptor blocking agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/387,028 US7030152B1 (en) | 1997-04-02 | 1999-08-31 | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| US09/387,028 | 1999-08-31 | ||
| PCT/US2000/024251 WO2001015744A1 (fr) | 1999-08-31 | 2000-08-31 | Marqueurs inflammatoires systemiques en tant qu'outils diagnostiques dans la prevention des maladies atherosclereuses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003508453A JP2003508453A (ja) | 2003-03-04 |
| JP2003508453A5 true JP2003508453A5 (fr) | 2007-11-01 |
Family
ID=23528141
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001520155A Pending JP2003508453A (ja) | 1999-08-31 | 2000-08-31 | アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1212101A1 (fr) |
| JP (1) | JP2003508453A (fr) |
| AU (1) | AU782386C (fr) |
| CA (1) | CA2381926A1 (fr) |
| WO (1) | WO2001015744A1 (fr) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517468A (en) | 1999-08-30 | 2004-02-27 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| IL154175A0 (en) | 2000-08-05 | 2003-07-31 | Glaxo Group Ltd | 17. beta.-carbothioate 17. alpha-arylcarbonyloxyloxy androstane derivatives as anti-inflammatory agents |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| MY138301A (en) | 2001-01-26 | 2009-05-29 | Schering Corp | The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| EP1413331B1 (fr) | 2001-01-26 | 2007-10-03 | Schering Corporation | Combinaisons de l'activateur du récepteur du peroxisome (PPAR) fenofibrate avec l'inhibiteur d'absorption de stérol ezetimibe pour des indications vasculaires |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| MXPA03009940A (es) | 2001-04-30 | 2004-01-29 | Glaxo Group Ltd | DERIVADOS ANTI-INFLAMATORIOS DE 17. BETA-CARBOTIOATO ESTER DE ANDROSTANO CON UN GRUPO DE ESTER CICLICO EN LA POSICIoN 17.ALFA. |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2002336609B2 (en) | 2001-09-21 | 2006-08-24 | Merck Sharp & Dohme Corp. | Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| KR20040068544A (ko) | 2001-11-05 | 2004-07-31 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 아테롬성 동맥경화증의 예후 표지로서의 가용성 ｃｄ40ｌ(ｃｄ154) |
| PL373787A1 (en) * | 2002-05-03 | 2005-09-19 | Alcon Inc. | Method of treating vascular endothelial growth factor mediated vascular disorders using amfenac or nepafenac |
| JP2006508188A (ja) | 2002-11-06 | 2006-03-09 | シェーリング コーポレイション | 脱髄の処置のためのコレステロール吸収インヒビター |
| GB0229747D0 (en) | 2002-12-20 | 2003-01-29 | Axis Shield Asa | Assay |
| WO2004081003A1 (fr) | 2003-03-07 | 2004-09-23 | Schering Corporation | Composes d'azetidinone substitues, leurs formulations et leur utilisation pour traiter l'hypercholesterolemie |
| MXPA05009502A (es) | 2003-03-07 | 2005-10-18 | Schering Corp | Compuestos de azetidinona sustituidos, formulaciones y usos de los mismos para el tratamiento de hipercolesterolemia. |
| US7235543B2 (en) | 2003-03-07 | 2007-06-26 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2005020984A2 (fr) * | 2003-08-29 | 2005-03-10 | Aaipharma Inc. | Methode de reduction du stress oxydatif |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| JP2007538024A (ja) * | 2004-05-19 | 2007-12-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アミロイドベータペプチドのレベル変化に関連する疾患及び状態の治療方法及び新規エノールカルボキサミド化合物 |
| US9274126B2 (en) | 2009-11-13 | 2016-03-01 | Bg Medicine, Inc. | Risk factors and prediction of myocardial infarction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2239801T3 (es) * | 1997-04-02 | 2005-10-01 | The Brigham And Women's Hospital, Inc. | Uso de un agente para disminuir el riesgo de enfermedad cardiovascular. |
| SK138799A3 (en) * | 1997-04-18 | 2001-01-18 | Searle & Co | Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders |
-
2000
- 2000-08-31 JP JP2001520155A patent/JP2003508453A/ja active Pending
- 2000-08-31 AU AU71103/00A patent/AU782386C/en not_active Expired
- 2000-08-31 WO PCT/US2000/024251 patent/WO2001015744A1/fr active IP Right Grant
- 2000-08-31 CA CA002381926A patent/CA2381926A1/fr not_active Abandoned
- 2000-08-31 EP EP00959851A patent/EP1212101A1/fr not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003508453A5 (fr) | ||
| HUP0100495A3 (en) | Use of prostaglandin (pge2)receptor 4 (ep4)selective agonists for producing pharmaceutical compositions suitable for the treatment of acute and chronic renal failure | |
| DZ2936A1 (fr) | Composition nouvelle à libération modifiée pour letraitement du diabète. | |
| HK1047693A1 (zh) | 治疗全身性焦虑障碍的环苯扎林及其组合物 | |
| NO20025586L (no) | Inhibitorer for 11-beta-hydroxy steroid dehydrogenase type 1 | |
| AU6872201A (en) | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition | |
| WO2001070212A3 (fr) | Methode et composition permettant de prevenir et de diminuer les symptomes de la menopause | |
| EE200100293A (et) | Kontrollitud vabanemisega ravivorm, mis sisaldab GnRH-II | |
| DK0867178T3 (da) | Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser | |
| MXPA03005155A (es) | 1,2-difenilazetidinonas novedosas, procesos para su preparacion, farmacos que contienen compuestos y su uso para el tratamiento del metabolismo afectado de los lipidos. | |
| TR200003788A3 (tr) | Yavas salimli oral dozaj bilesim. | |
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| DE60037726D1 (de) | Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen | |
| PL357944A1 (en) | Intradermal-penetration agents for topical local anesthetic administration | |
| PL363218A1 (en) | Compositions for delivery of a cortisol antagonist | |
| DZ2752A1 (fr) | Composés et compositions pharmaceutiques pour le traitement du paludisme. | |
| BR9815747A (pt) | Composição para liberação de aroma | |
| CA2351720A1 (fr) | Systeme d'enrobage a liberation rapide masquant le gout | |
| ID27820A (id) | APLIKASI-APLIKASI PENGOBATAN POLIPEPTIDA MATURE FLINT (mFLINT) ATAU OPG3, BAGIAN KELOMPOK SUPER RESEPTOR TNF | |
| HK1047036A1 (zh) | 用於治疗偏头痛的选择性iglur5，受体拮抗剂 | |
| FR2820975B1 (fr) | Composition pour application topique comprenant au moins un hydroxystilbene et au moins un polyol pour solubiliser l'hydroxystilbene | |
| CA2378428A1 (fr) | Utilisation d'antagonistes de cgrp et d'inhibiteurs de secretion cgrp servant a lutter contre les bouffees de chaleur de la menopause | |
| EP1003494A4 (fr) | (d)-METHADONE, ANALGESIQUE NON OPIOIDE | |
| EP1284723A4 (fr) | Compositions et methodes pour traiter des troubles associes a l'hyperlipidemie | |
| JP2004500325A5 (fr) |